Search hospitals > North Carolina > Raleigh
UNC Rex Healthcare
Claim this profileRaleigh, North Carolina 27607
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Peripheral Arterial Disease
Conducts research for Tumors
Conducts research for Head and Neck Cancers
76 reported clinical trials
7 medical researchers
Summary
UNC Rex Healthcare is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Peripheral Arterial Disease, Tumors, Head and Neck Cancers and other specialties. UNC Rex Healthcare is involved with conducting 76 clinical trials across 149 conditions. There are 7 research doctors associated with this hospital, such as Lisa Carey, JoEllen Speca, Ranjit Joseph, and Samantha L Margulies, MD.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
2Cancer
Global LeaderHER2 positive
ER positive
PR positive
Top PIs
Lisa CareyUniversity of North Carolina at Chapel Hill3 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
13 reported clinical trials
25 drugs studied
JoEllen SpecaUNC Rex Healthcare1 year of reported clinical research
Studies Breast Cancer
Studies Recurrence
3 reported clinical trials
7 drugs studied
Ranjit JosephRex Hematology Oncology Associates-Cary4 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
2 reported clinical trials
6 drugs studied
Samantha L Margulies, MDRex Hospital3 years of reported clinical research
Studies Urinary Incontinence
Studies Bedwetting
1 reported clinical trial
2 drugs studied
Clinical Trials running at UNC Rex Healthcare
Breast Cancer
Prostate Cancer
Recurrence
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Prostate Adenocarcinoma
Tumors
Bone Metastasis
Atrial Fibrillation
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UNC Rex Healthcare?
UNC Rex Healthcare is a medical facility located in Raleigh, North Carolina. This center is recognized for care of Breast Cancer, Cancer, Peripheral Arterial Disease, Tumors, Head and Neck Cancers and other specialties. UNC Rex Healthcare is involved with conducting 76 clinical trials across 149 conditions. There are 7 research doctors associated with this hospital, such as Lisa Carey, JoEllen Speca, Ranjit Joseph, and Samantha L Margulies, MD.